Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLASMACYTOKID: Gender and Puberty Impact on pDCs
NCT02956980Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Open-label trial (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Percentage of IFN1 producing pDCs at 1 day. Started Jun 2017; status: terminated.
Beyond the preview
Go deeper on NCT02956980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956980.